Skip to main content
SpringerLink
Log in

Antimicrobial Stewardship for Transplant Candidates and Recipients

  • Reference work entry
  • First Online:
Emerging Transplant Infections

  • 1100 Accesses

Abstract

Antimicrobial stewardship is an essential component of transplant programs to improve patient outcomes, reduce the threat of antimicrobial resistance, and lower the risk of drug toxicity. A multidisciplinary approach that leverages the existing team-based infrastructure of transplant programs and encompasses partnership with pharmacy, infection prevention, and microbiology is important for successful implementation. This chapter outlines the importance of stewardship in transplantation, describes implementation strategies, and provides examples of syndrome-or drug-specific antibiotic, antiviral, and antifungal stewardship targets for transplant patients. Finally, program process and outcome metrics should be chosen to assess the impact of interventions and identify opportunities for improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fishman N. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012;33(4):322–7.

    Article  Google Scholar 

  2. Dellit TH, Owens RC, Mcgowan JE, Gerding DN, Weinstein RA, Burke JP, et al. Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.

    Article  PubMed  Google Scholar 

  3. Barlam TF, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62(10):e51–77.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dela-Pena J, Kerstenetzky L, Schulz L, Kendall R, Lepak A, Fox B. Top 1% of inpatients administered antimicrobial agents comprising 50% of expenditures: a descriptive study and opportunities for stewardship intervention. Infect Control Hosp Epidemiol. 2017;38(3):259–65.

    Article  PubMed  Google Scholar 

  5. Revolinski SL, Munoz-Price LS. Clostridium difficile in immunocompromised hosts: a review of epidemiology, risk factors, treatment, and prevention. Clin Infect Dis. 2019;68(12):2144–53.

    Article  PubMed  Google Scholar 

  6. Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016;8(339):339ra71.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, et al. Effect of azithromycin on airflow decline–free survival after allogeneic hematopoietic stem cell transplant. J Am Med Assoc. 2017;318(6):557–66.

    Article  CAS  Google Scholar 

  8. Weber D, Jenq RR, Peled JU, Taur Y, Hiergeist A, Koestler J, et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(5):845–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Montassier E, Al-Ghalith GA, Ward T, Corvec S, Gastinne T, Potel G, et al. Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection. Genome Med. 2016;8(1):49.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Seo SK, Lo K, Abbo LM. Current state of antimicrobial stewardship at solid organ and hematopoietic cell transplant centers in the United States. Infect Control Hosp Epidemiol. 2016;37(10):1195–200.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Echevarria K, Groppi J, Kelly AA, Morreale AP, Neuhauser MM, Roselle GA. Development and application of an objective staffing calculator for antimicrobial stewardship programs in the Veterans Health Administration. Am J Heal Pharm. 2017;74(21):1785–90.

    Article  Google Scholar 

  12. Abbo LM, Ariza-Heredia EJ. Antimicrobial stewardship in immunocompromised hosts. Infect Dis Clin N Am. 2014;28(2):263–79.

    Article  Google Scholar 

  13. American Nurses Association, Centers for Disease Control and Prevention. Redefining the antibiotic stewardship team: recommendations from the American Nurses Association/Centers for Disease Control and Prevention Workgroup on the role of registered nurses in hospital antibiotic stewardship practices. 2017.

    Google Scholar 

  14. Tyler LS, Cole SW, May JR, Miliares M, Valentino MA, Vermeulen LC, et al. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health Syst Pharm. 2008;65:1272–83.

    Article  PubMed  Google Scholar 

  15. Quadri F, Mazer-Amirshahi M, Fox ER, Hawley KL, Pines JM, Zocchi MS, et al. Antibacterial drug shortages from 2001 to 2013: implications for clinical practice. Clin Infect Dis. 2015;60(12):1737–42.

    Article  PubMed  Google Scholar 

  16. Chemaly RF, Aitken SL, Wolfe CR, Jain R, Boeckh MJ. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18(4):634–6.

    Article  CAS  PubMed  Google Scholar 

  17. McCarthy M. Drug’s 5000% price rise puts spotlight on soaring US drug costs. BMJ. 2015;351:h5114.

    Article  PubMed  CAS  Google Scholar 

  18. Robilotti E, Holubar M, Seo SK, Deresinski S. Feasibility and applicability of antimicrobial stewardship in immunocompromised patients. Curr Opin Infect Dis. 2017;30(4):346–53.

    Article  PubMed  Google Scholar 

  19. Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol. 2012;33(4):338–45.

    Article  PubMed  Google Scholar 

  20. Kirk A, Pierce J, Doll M, Lee K, Pakyz A, Kim J, et al. Effect of carbapenem restriction on prescribing trends for immunocompromised wards at an academic medical center. Am J Infect Control. 2019;47(8):1035–7.

    Article  PubMed  Google Scholar 

  21. Yeo CL, Chan DSG, Earnest A, Wu TS, Yeoh SF, Lim R, et al. Prospective audit and feedback on antibiotic prescription in an adult hematology-oncology unit in Singapore. Eur J Clin Microbiol Infect Dis. 2012;31(4):583–90.

    Article  PubMed  Google Scholar 

  22. Horikoshi Y, Kaneko T, Morikawa Y, Isogai M, Suwa J, Higuchi H, et al. The north wind and the sun: pediatric antimicrobial stewardship program combining restrictive and persuasive approaches in hematology-oncology ward and hematopoietic stem cell transplant unit. Pediatr Infect Dis J. 2018;37(2):164–8.

    Article  PubMed  Google Scholar 

  23. Hurst AL, Child J, Pearce K, Palmer C, Todd JK, Parker SK. Handshake stewardship: a highly effective rounding-based antimicrobial optimization service. Pediatr Infect Dis J. 2016;35(10):1104–10.

    Article  PubMed  Google Scholar 

  24. Messacar K, Campbell K, Pearce K, Pyle L, Hurst AL, Child J, et al. A handshake from antimicrobial stewardship opens doors for infectious disease consultations. Clin Infect Dis. 2017;64(10):1449–52.

    Article  PubMed  Google Scholar 

  25. Rosa R, Simkins J, Camargo JF, Martinez O, Abbo LM. Solid organ transplant antibiograms: an opportunity for antimicrobial stewardship. Diagn Microbiol Infect Dis. 2016;86(4):460–3.

    Article  PubMed  Google Scholar 

  26. Korayem GB, Zangeneh TT, Matthias KR. Recurrence of urinary tract infections and development of urinary-specific antibiogram for kidney transplant recipients. J Glob Antimicrob Resist. 2018;12:119–23.

    Article  PubMed  Google Scholar 

  27. Rosa R, Rudin SD, Rojas LJ, Perez-Cardona A, Aragon L, Nicolau DP, et al. Application of “precision medicine” through the molecular characterization of extensively drug-resistant Klebsiella pneumoniae in a multivisceral transplant patient. Clin Infect Dis. 2017;65(4):701–2.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Tamma PD, Miller MA, Cosgrove SE. Rethinking how antibiotics are prescribed. JAMA. 2019;321(2):139–40.

    Article  PubMed  Google Scholar 

  29. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. JAMA. 2019.

    Google Scholar 

  30. Huang KHG, Cluzet V, Hamilton K, Fadugba O. The impact of reported beta-lactam allergy in hospitalized patients with hematologic malignancies requiring antibiotics. Clin Infect Dis. 2018;67(1):27–33.

    Article  PubMed  Google Scholar 

  31. Khumra S, Chan J, Urbancic K, Worland T, Angus P, Jones R, et al. Antibiotic allergy labels in a liver transplant recipient study. Antimicrob Agents Chemother. 2017;61(5):10–2.

    Article  Google Scholar 

  32. Trubiano JA, Leung VK, Chu MY, Worth LJ, Slavin MA, Thursky KA. The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients. Antimicrob Resist Infect Control. 2015;4(1):1–4.

    Article  Google Scholar 

  33. Trubiano JA, Thursky KA, Stewardson AJ, Urbancic K, Worth LJ, Jackson C, et al. Impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: a multicenter evaluation. Clin Infect Dis. 2017;65(1):166–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ram R, Halavy Y, Amit O, Paran Y, Katchman E, Yachini B, et al. Extended vs bolus infusion of broad-spectrum β-lactams for febrile neutropenia: an unblinded, randomized trial. Clin Infect Dis. 2018;67(8):1153–60.

    Article  CAS  PubMed  Google Scholar 

  35. Hand J. Strategies for antimicrobial stewardship in solid organ transplant recipients. Infect Dis Clin N Am. 2018;32(3):535–50.

    Article  Google Scholar 

  36. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the british society for medical mycology. J Antimicrob Chemother. 2014;69(5):1162–76.

    Article  CAS  PubMed  Google Scholar 

  37. Tamma PD, Conley AT, Cosgrove SE, Harris AD, Lautenbach E, Amoah J, et al. Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae Bacteremia. JAMA Intern Med. 2019;179(3):316–23.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Åsberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9(5):1205–13.

    Article  PubMed  CAS  Google Scholar 

  39. Vicente M, Al-Nahedh M, Parsad S, Knoebel RW, Pisano J, Pettit NN. Impact of a clinical pathway on appropriate empiric vancomycin use in cancer patients with febrile neutropenia. J Oncol Pharm Pract. 2017;23(8):575–81.

    Article  CAS  PubMed  Google Scholar 

  40. Nucci M, Landau M, Silveira F, Spector N, Pulcheri W. Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides. Infect Control Hosp Epidemiol. 2001;22(10):651–3.

    Article  CAS  PubMed  Google Scholar 

  41. la Martire G, Robinson C, Oubaya N, Lepeule R, Beckerich F, Leclerc M, et al. De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome. Eur J Clin Microbiol Infect Dis. 2018;37(10):1931–40.

    Article  PubMed  CAS  Google Scholar 

  42. Pakakasama S, Surayuthpreecha K, Pandee U, Anurathapan U, Maleewan V, Udomsubpayakul U, et al. Clinical practice guidelines for children with cancer presenting with fever to the emergency room. Pediatr Int. 2011;53(6):902–5.

    Article  PubMed  Google Scholar 

  43. Morgan DJ, Malani P, Diekema DJ. Diagnostic stewardship – leveraging the laboratory to improve antimicrobial use. J Am Med Assoc. 2017;318(7):607–8.

    Article  Google Scholar 

  44. Morgan DJ, Croft LD, Deloney V, Popovich KJ, Crnich C, Srinivasan A, et al. Choosing Wisely in healthcare epidemiology and antimicrobial stewardship. Infect Control Hosp Epidemiol. 2016;37(7):755–60.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Madden GR, Sifri CD. Reduced Clostridioides difficile tests among solid organ transplant recipients through a diagnostic stewardship bundled intervention. Ann Transplant. 2019;24:304–11.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Mizusawa M, Small BA, Hsu Y-J, Sharara SL, Advic E, Kauffman C, et al. Prescriber behavior in Clostridium difficile testing: a 3-hospital diagnostic stewardship intervention. Clin Infect Dis. 2019;69(11):2019–2021. https://doi.org/10.1093/cid/ciz295

  47. Alonso CD, Marr KA. Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis. 2013;26(4):326–31.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kamboj M, Brite J, Aslam A, Kennington J, Babady NE, Calfee D, et al. Artificial differences in clostridium difficile infection rates associated with disparity in testing. Emerg Infect Dis. 2018;24(3):584–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Stohs E, Chow VA, Liu C, Bourassa L, Miles-Jay A, Knight J, et al. Limited utility of outpatient surveillance blood cultures in hematopoietic cell transplant recipients on high-dose steroids for treatment of acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2019;25(6):1247–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Krantz EM, Zier J, Stohs E, Ogimi C, Sweet A, Marquis S, et al. Antibiotic prescribing and respiratory viral testing for acute upper respiratory infections among adult patients at an Ambulatory Cancer Center. Clin Infect Dis 2019;1–8.

    Google Scholar 

  51. Rosa RG, Goldani LZ, dos Santos RP. Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study. BMC Infect Dis. 2014;14:286.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Beyar-Katz O, Dickstein Y, Borok S, Vidal L, Leibovici L, Paul M. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2017;6:CD003914. https://doi.org/10.1002/14651858.CD003914.pub4.

  53. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005;5(7):431–9.

    Article  CAS  PubMed  Google Scholar 

  54. Libuit J, Whitman A, Wolfe R, Washington CS. Empiric vancomycin use in febrile neutropenic oncology patients. Open Forum Infect Dis. 2014;1(Suppl 1):1–8.

    Google Scholar 

  55. Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37(3):382–9.

    Article  CAS  PubMed  Google Scholar 

  56. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients. IDSA Guidel. 2010;52(4):e56–93.

    Google Scholar 

  57. Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2016;14(7):882–913.

    Article  CAS  Google Scholar 

  58. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98(12):1826–35.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Pillinger KE, Bouchard J, Withers ST, Mediwala K, Mcgee EU, Gibson GM, et al. Inpatient antibiotic stewardship interventions in the adult oncology and hematopoietic stem cell transplant population: a review of the literature. Ann Pharmacother. 2019;1060028019890886. https://doi.org/10.1177/1060028019890886. [Epub ahead of print]

  60. Aguilar-Guisado M, Espigado I, Martín-Peña A, Gudiol C, Royo-Cebrecos C, Falantes J, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017;4(12):e573–83.

    Article  PubMed  Google Scholar 

  61. Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):1611–5.

    Article  PubMed  Google Scholar 

  62. Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33:e13507.

    Article  Google Scholar 

  63. Origüen J, López-Medrano F, Fernández-Ruiz M, Polanco N, Gutiérrez E, González E, et al. Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial. Am J Transplant. 2016;16(10):2943–53.

    Article  PubMed  Google Scholar 

  64. Moradi M, Abbasi M, Moradi A, Boskabadi A, Jalali A. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. Urol J. 2005;2(1):32–5.

    PubMed  Google Scholar 

  65. El Amari EB, Hadaya K, Bühler L, Berney T, Rohner P, Martin P-Y, et al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dial Transplant. 2011;26(12):4109–14.

    Article  PubMed  Google Scholar 

  66. Vidal E, Torre-Cisneros J, Blanes M, Montejo M, Cervera C, Aguado JM, et al. Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort. Transpl Infect Dis. 2012;14(6):595–603.

    Article  CAS  PubMed  Google Scholar 

  67. Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012;46(4):558–66.

    Article  PubMed  CAS  Google Scholar 

  68. Foolad F, Aitken SL, Shigle TL, Prayag A, Ghantoji S, Ariza-Heredia E, et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. Clin Infect Dis. 2019;68(10):1641–9.

    Article  CAS  PubMed  Google Scholar 

  69. Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31(8):839–44.

    Article  PubMed  Google Scholar 

  70. Wang N, Athans V, Neuner E, Bollinger J, Spinner M, Brizendine K. A pharmacist-driven antimicrobial stewardship intervention targeting cytomegalovirus viremia in ambulatory solid organ transplant recipients. Transpl Infect Dis. 2018;20(6):1–8.

    Article  CAS  Google Scholar 

  71. Ananda-Rajah MR, Slavin MA, Thursky KT. A case for antifungal stewardship. Curr Opin Infect Dis. 2012;25(1):107–15.

    Article  PubMed  Google Scholar 

  72. Hamdy RF, Zaoutis TE, Seo SK. Antifungal stewardship considerations for adults and pediatrics. Virulence. 2017;8(6):658–72.

    Article  PubMed  Google Scholar 

  73. Schwartz IS, Patterson TF. The emerging threat of antifungal resistance in transplant infectious diseases. Curr Infect Dis Rep. 2018;20(3):1–10.

    Article  Google Scholar 

  74. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12(3):220–9.

    Article  CAS  PubMed  Google Scholar 

  75. Urbancic KF, Thursky K, Kong DCM, Johnson PDR, Slavin MA. Antifungal stewardship: developments in the field. Curr Opin Infect Dis. 2018;31(6):490–8.

    Article  PubMed  Google Scholar 

  76. Hand J, Patel G. Antimicrobial stewardship in transplant patients. Curr Opin Organ Transplant. 2019;24(4):497–503.

    Article  PubMed  Google Scholar 

  77. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–60.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Catherine Liu

  2. Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA

    Catherine Liu

  3. Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

    Erica J. Stohs

Authors
  1. Catherine Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erica J. Stohs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine Liu .

Editor information

Editors and Affiliations

  1. Immunocompromised Host Service Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Michele I. Morris

  2. Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Camille Nelson Kotton

  3. Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA

    Cameron R. Wolfe

Section Editor information

  1. Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Michele I. Morris

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Liu, C., Stohs, E.J. (2021). Antimicrobial Stewardship for Transplant Candidates and Recipients. In: Morris, M.I., Kotton, C.N., Wolfe, C.R. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-25869-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25869-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25868-9

  • Online ISBN: 978-3-030-25869-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation